New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
07:04 EDTNURONeuroMetrix announces initial commercial shipment of SENSUS system
NeuroMetrix has initiated commercial shipment of its SENSUS Pain Management System which received final FDA clearance on November 28, 2012. SENSUS is a transcutaneous electrical nerve stimulator intended for the symptomatic relief and management of chronic intractable pain.
News For NURO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
07:15 EDTNURONeuroMetrix reports over 200,000 members assessed with DPNCheck
Subscribe for More Information
August 18, 2015
09:23 EDTNUROOn The Fly: Pre-market Movers
Subscribe for More Information
07:04 EDTNURONeuroMetrix reports 'positive' clinical results for Quell
NeuroMetrix announced preliminary results from a clinical study of the Quell Wearable Pain Relief device in subjects with chronic pain. The study was an open-label, single-arm, flexible dosing, 60-day trial of Quell for treatment of chronic pain. The average age of the subjects was 56 years and 45% were female. Most had chronic pain for 1-10 years, although nearly a quarter had more than 15 years of pain. The subjects had 3 sites of pain on average and complex medical histories with arthritis, diabetes, sciatica, and fibromyalgia as the most common. At baseline, 40% of the subjects had severe pain, with the remaining 60% reporting moderate pain. The primary outcome measure was strongly positive with 81% of subjects rating Quell therapy as improving their chronic pain and overall health on a Patient Global Impression of Change scale. Secondary outcome measures were also positive with 67% of subjects reporting a reduction in use of pain medications. Pain intensity, relief, and interference, which were assessed using the Brief Pain Inventory, showed statistically significant improvement over the 60-day study period. The largest measured changes were in pain relief and interference with sleep, general activity, and walking ability.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use